Topical intranasal steroid spray is often used to treat allergic and nonallergic rhinitis, and epistaxis isa common side effect. Theprospective, observational study described wasdesi gned to determine the incidence of epistaxis and the relationship between theside of bleeding and the hand used to administer the spray, as well as the handedness of thepatient, in a noninvestigational, real-world setting.Of 559 consecutive patients using an intranasal steroid for more than 3 months,28 patients (5%) reported epistaxis within the prior 2 months. Of the 32 reported sides of bleeding (unilateral and bilateral combined), 25 episodes (78%) were on the same side as the hand used to apply thespray.A strong correlation wasfound between theside of bleeding and both the hand used (p < 0.001) and the handedness of thepatient (p < 0.002). Patientinstruction on technique may reduce the incidenceof epistaxis.
Introduction
Topical intranasal steroid (INS) sprays are commonly used and have been shown to be effective and safe for treating seasonal and perennial allergic rhinitis, nonallergic rhinitis, and nasal pol yps.' They have also been used for other acute and ch ronic nasal conditions, including chronic rhinosinusitis,' acute rhinosinusitis, th e common cold,' and other inflammatory conditions From of the nose and sinuses. These agents have minimal side effects, and their good safety profile' has resulted in appro val of their use in small children.
Epistaxis is a common side effect of INS spray use. Th e incidence reported in clinical trials is usually about 5%, which is only 1 to 3% greater th an the incidence reported with the use of placebo.' Th e incidence appears to have decreased with th e universal adoption of aqueo us-based INS. Repo rts suggest th at episod es of epistaxis are usually mino r and self-limited. They may be the dir ect effect of the corticosteroid, preservative," pressure of the application, or technique used.'
Recent anecdotal findin gs suggest a corr elation between th e handedness of the patient and the side of bleeding. In a study published in 2004, approxim ately 80% of episodes occurred on the dominant-hand side,' which was one factor prompting my colleagues and me to recommend that patients direct the spray awayfrom the septum.' The study was un controlled, nonprospective, and did not evaluate the incidence ofepistaxis,however. No studies have evaluated a possible correl ation between this incidence and the ind ications for use.
The present , pro spective study was designed to evaluate th e incidence of epistaxis with use of INS spray and th e relationship between dom inant-hand use and side of bleedin g in a noninvestigation al setting. Indications for use and frequency of epistaxis were also evaluated.
Study method
The study was approved by the Institutional Review Board of Henry Ford Hospit al and Medi cal Group, and methods to ensure pati ent confidenti ality were m aintained. Th e study was performed in both a central-city academ ic site and a suburban privat e practice setting. Consecutive patients who were seen over the course of 1 year, had used INS spr ay for at least 3 consecutives m onths prior to pr esentation, and had not specifically www.entjo urnal.com • 463 been instructed by a healthcare provider to avoid spraying against the septum were enrolled.
Indications for use were determined for all patients. Because the study was observational, pat ients had confirmatory allergy testing only when it was part of their routine clinical care.Adiagnosis of chronic rhinosinusitis was made on the basis of the criteria established by the Sinus and Allergy Health Partnership and endorsed by the Amer ican Academy of Ot olaryngology-Head an d Neck Surge ry' and, subsequently, by five m ajor otolaryngology and allergy societies."
A diagnosis of allergic rhinitis was determined by a history of allergen-me diated nasal symp toms and, in a majority of patient s, allergy confirma tio n with skin or in vitro testing. A diagnosis of nonallergic rhinitis was determi ned by th e absence of medical histor y suggesting allergy and th e presence of known environmental precipitants of nasal symptoms, with or without negative skin tests.
All patients were asked whether they had experienced epistaxis within the prior 2 months. The definition of epistaxis was left up to the patient, although a small amo unt ofblood-streaked mucus on a single occasion of nose blowing was not considered to be epistaxis. Patien ts reporting one or more episodes of epistaxis were asked the side of bleeding, which hand th ey typically used to deliver the spray, and which han d was dominant. They underwent anter ior nasal exam inatio n and/o r nasal endosco py, and possible sites of bleeding were identified if a small clot, an ope n sore, or prominent blood vessels were seen.
Formal stat istical analysis was per for me d. Data consisted of ma tched pairs: the side where INS was sprayed with th e hand on that side and the side where it was not. The epistaxis rate for each side was computed along with an exact 95% confide nce interval (CI). The paired incidence rates were compared using the McNemar test.
Significance was judged as p< 0.05. The same approach was used for the matched pairs defined by the dominant and nondominant hand.
Results
Of the 559 consecutive patients who met study criteria, 211had chronic rhinosinusitis , 226 had allergic rhinitis, and 122 had no nallergic rhinitis. At least one episo de of epistaxis was reported by 28 patients (5%): from one side on ly by 24 and from both sides by 4 (for a total of32 sides). In 20 ofthe pat ients, evidence ofa possible source of bleedin g was found duri ng the office visit. In every case, the septum was the site of potential bleeding.
Of the 28 patients reporting epista xis, 17 (61%) had chronic rhinosinusitis (13 of them with polyps and 10 with a history of surgical therapy), 6 (21%) had allergic rhinitis, and 5 (18% ) had nonallergic rhinitis. Patients with chronic rhinosinusitis had a higher reported incidence of epistaxis (8%) than did patients with allergic rhinitis (3%) or non allergic rhinitis (3.2%).
Of the 32 reported sides of epistaxis, 25 (78%) were on the same side as the hand used for spraying. The incidence rate of epistaxis on the same side as th e hand used was 4.5% (25/559) (95% CI, 2.9 to 6.5), in contrast to an incidence rate of 1.3% (7/559) (0.5 to 2.6) on th e other side. Th e two rates are significantly different (p < 0.001). In subje cts with epistax is on on ly one side, 86% (67.6 to 97.4) had it on the same side as the hand used to spray the INS.
Onl y one patient did not use the dominant hand to spray the INS. This right-handed subject used the left hand and exper ienced bleeding on the left.The incidence rate for epistaxis on the side of the domina nt hand was 4.3% (24/559) (2.8 to 6.3), and the incidence rate on the nondomina nt side was 1.4% (8/559) (0.6 to 2.8).
These rates differ at a value of p < 0.002. In subjects with epistaxis on only one side, 83% (62.6 to 95.3) had it on the same side as the dominant hand.
Discussion
The safety and efficacy of INS spray use is well documented.l-v Reported side effects are few, but th e one reported most often and seemingly of greatest concern to both patient s and physicians is epistaxis. Typically, it is mi nor and self-limited, and in clinical trials its rate is not substa ntially higher th an that occurring with placebo use." Some experts suggest that the risk of epistaxis is increased by spraying the INS direc tly at the septum, th us causing mechanical injur y. The probability of such an occurrence cou ld be expected to be increased on the same side as the hand used to app ly the spray and reduced on the opposite side, where the spray is more likely to be angled toward the lateral nasal wall. Earlier observational assessments suggested these findings , but evaluation was poorly controlled. ' The current prospective study confirms that epistaxis is more likely to occur on the same side as the han d used to spray th e INS. On the basis of current data, recommendi ng th at patients direct the spray toward the lateral aspect of th e nose, and perhaps use th e left hand
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to spray the right nostril and the right hand to spray the left nostril, seems reasonable.'
In prospective clinical trials,the incidence ofepi staxis with INS use has been approximately 5%,4and this study suggests a comparable incidence in a real-world setting using similar criteria to define epistaxis.
Most prospective trials have evaluated patients with allergic rhinitis. In the present study, the incidence of epistaxis in these patients was 3%, which is lower than the rates typically seen in controlled trials. This difference is not substantial and might be attributable to the rigorous recording of adverse events in clinical trials, differences in definitions of epistaxis, or other factors related to trial methods. Patients in a real-world setting might ignore slight bleeding or believe ittoo insignificant to report. Also, it is possible that the rates of bleeding noted in clinical trials are greater than what is seen in clinical practice.
In a large survey study of U.S. households published in 2004, the incidence of epistaxis in the community was evaluated.' Responses were elicited from 2,511 geographically and demographically representative households in March and from 2,027 different households in October. Minor recurring epistaxis in one or more household members (overall average, 1.4 members) was reported by 31% of the March group and 29% of the October group. If data were extrapolated to the entire U.S. population, it would translate to 45.1 million people experiencing epistaxis,or 15.8% ofthe population. 7 The time frame in the survey study was not well defined, so comparing the general incidence of epistaxis to the . incidence in INS users is difficult.
Results of the present study strongly suggest that the incidence ofepistaxis in INS users is relatively small , even among those not specifically instructed on appropriate techniques. With patients instructed to direct the spray toward the lateral nasal wall and avoid the septum, the incidence would likely decrease, since potential bleeding sites were found on the septum onlyon physical examination. These findings may have implications for physician instructions to patients, clinical trials, and identification of proper technique in development, submission, and approval of new intranasal steroids.
